AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
The following information and Exhibits99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing.On January 7, 2019, AMAG Pharmaceuticals, Inc. (“the Company”) issued a press release providing a business update, including preliminary unaudited fourth quarter and annual 2018 financial results and financial guidance for 2019. A copy of the Company’s press release is furnished herewith as Exhibit99.1.
Item 7.01. Regulation FD Disclosure.
The following information and Exhibit99.2 attached hereto shall not be deemed “filed” for purposes of Section18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.The Company will present further details on the matters noted above at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on January9, 2019, which presentation will be accessible by a live audio webcast through the Company’s website at www.amagpharma.com on January9, 2019 at 7:30 a.m.Pacific Time (10:30 a.m.Eastern Time). During the conference, the Company intends to conduct meetings with third parties in which a corporate slide presentation will be presented. A copy of the Company’s slide presentation, which will be referenced during the conference, including the Company’s webcast presentation, is furnished herewith as Exhibit 99.2.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
The Company hereby furnishes the following exhibits:
AMAG PHARMACEUTICALS INC. Exhibit
EX-99.1 2 jpmex991.htm EXHIBIT 99.1 Exhibit FOR IMMEDIATE RELEASEAMAG Pharmaceuticals Announces Preliminary 2018 Financial Results and Provides 2019 Financial GuidanceAchieves 2018 revenue of between $471 million and $476 million,…
To view the full exhibit click here
About AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
